ST. JOSEPH, Mich., April 22 /PRNewswire/ -- GeneGo, Inc., the leading provider of software and databases for systems biology and pathway analysis, today announced that the Chinese University of Hong Kong, Pediatric department will be using GeneGo's MetaCore(TM). Broad coverage of biomarkers and drug targets for a large variety of diseases in MetaCore was an important factor for the decision to license MetaCore, as well as species-specific content for the main animal models used in disease research.
"We are very pleased to have the Chinese University of Hong Kong as a customer as we extend our reach in Asia," said Julie Bryant, VP business development. "Hong Kong is a very sophisticated market with top notch researchers in oncology and other key diseases, and we are glad that the CUHK group has chosen MetaCore. Disease area specific content is one of our important development goals for the next 3 years."
GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.6(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.6(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com
MetaCore(TM), MetaBase(TM) MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.
Copyright©2008 PR Newswire.
All rights reserved